唑来膦酸联合放疗治疗骨转移瘤的临床观察

Zoledronic Acid Combined with Radiotherapy in the Treatment of Bone Metastases Carcinoma

目的探讨唑来膦酸联合放疗治疗骨转移瘤的临床疗效和安全性。方法选择60例骨转移瘤患者,随机均分为2组,观察组30例给予唑来膦酸联合放疗,对照组30例仅单纯行放疗。结果观察组镇痛有效率93.3%,高于对照组的73.3%(P<0.05);骨转移灶的影像学有效率66.7%,对照组56.7%,差异无统计学意义(P>0.05)。2组毒副反应相似,均在可控制范围内。结论唑来膦酸联合放疗治疗骨转移瘤疗效较满意,毒副反应可耐受。

Objective To investigate the clinical efficacy and safety of zoledronic acid combined with radiotherapy in the treatment of bone metastases carcinoma. Methods Sixty patients with bone metastases carcinoma were randomized into two groups. Thirty patients in the observation group were given with zoledronic acid combined with radiotherapy, and 30 patients in the control group were given the mere radiotherapy. Results The analgesia response rate of the observation group was obviously higher than that of the control group （93.3% vs 73.3% ,P 〈 0.05 ）. The imaging finding response rate of the observation group was 66.7% ,and was 56.7% of the control group （P 〉 0.05 ）. The main toxicities of the two group were light and similar. Conclusion Zoledronic acid combined with radiotherapy is effective and safe in the treatment of bone metastases carcinoma.